BRAF and melanoma: Indeed, both targeted therapy and immunotherapy with immune checkpoint inhibitors are possible therapeutic options for patients with BRAF-mutant melanoma, and the availability of novel biomarkers able to predict patients’ responses to therapy and to estimate their expectancy of PFS and OS may potentially help clinicians choose the optimal therapeutic protocol.